Balance D Hf
Posted Date: Mar 5, 2025
- Investigator: Juliane Vierecke
- Specialties:
- Type of Study: Drug
This is a Phase III study in patients with chronic HF (Heart Failure) and impaired kidney function who had a recent HF event. The aim is to evaluate the effect of a once-daily, oral balcinrenone/dapagliflozin compared to a once daily, oral dapagliflozin on CV (cardiovascular) death and HF events. Balcinrenone is a selective mineralocorticoid receptor (MR) modulator that is also expected to reduce the risk of hyperkalemia with MRAs.
Criteria:
Heart Failure Patients With Chronic Kidney Disease
Keywords:
Balcinrenone/Dapagliflozin For Hf With Ckd
For More Information:
Harshada More
5135584739
morehp@ucmail.uc.edu